|Bid||2.1700 x 1000|
|Ask||2.2300 x 2200|
|Day's Range||2.1538 - 2.2700|
|52 Week Range||2.1100 - 6.9830|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
During Q4, Otonomy (NASDAQ:OTIC) brought in sales totaling $53.00 thousand. However, earnings decreased 2.2%, resulting in a loss of $10.29 million. Otonomy collected $50.00 thousand in revenue during Q3, but reported earnings showed a $10.52 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Otonomy posted an ROCE of -0.16%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on OTIC Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. In Otonomy's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q4 Earnings Recap Otonomy reported Q4 earnings per share at $-0.2/share, which beat analyst predictions of $-0.22/share. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Monday's Pre-Market SessionEarnings Scheduled For February 11, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis," said Chief Executive David Weber. He said the company's focus turns to the "strong pipeline," highlighted by the "successful" clinical trial results of its tinnitus and hearing loss treatments, with clinical readouts anticipated in mid-2022. Weber said he expects the company's existing cash balance is enough to to achieve the clinical readouts. The stock has rallied 51.8% over the past 12 months through Friday, while the iShares Nasdaq Biotechnology ETF has advanced 35.1% and the S&P 500 has gained 17.1%.